Skip to content
Screener

Amneal Pharmaceuticals, Inc. AMRX EPS (Diluted)

EPS (Diluted) at other companies

Pfizer logo
PfizerPFE
-$0.04-108%
McKesson logo
McKessonMCK
$5.15-17.6%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$1.05+192%
Cencora logo
CencoraCOR
$3.94+11.9%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$4.43+391%
Emergent Biosolutions logo
Emergent BiosolutionsEBS
-$3.49-1,486%

Other financials

Income statement

See full
Revenue$796.2M+9.9%
Gross profit$334.5M+16.9%
Operating income$129.8M+16.5%
Net income$57.7M+157%

Balance sheet

See full
Cash & equivalents$127.6M+78.4%
Total debt$2.6B+18.0%
Total equity$33.0M+129%
Total assets$3.8B+10.3%

Cash flow

See full
Operating cash flow-$21.2M-125%
CapEx$30.7M+34.5%
Free cash flow-$51.9M-185%

Valuation

See full
Market cap$5.89B+134%
Enterprise value$8.34B+80.1%
P/E37.5×-710×
P/S1.9×+1.0×

Profitability

See full
Gross margin39.3%+1.7pp
Operating margin14.6%+1.4pp
Net margin5%+4.9pp
FCF margin4.1%-5.8pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity77.8×—
Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001723128-26-000031
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Less: Net income attributable to non-controlling interests(11,952)(13,193)(27,696)(25,616)
Net income attributable to Amneal Pharmaceuticals, Inc.$57,662$22,417$119,918$34,612
Net income per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders:
Basic$0.18$0.07$0.38$0.11
Diluted$0.18$0.07$0.37$0.11
Weighted-average common shares outstanding:
Basic319,200313,739317,620312,404
Diluted328,102322,363328,527323,171

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s EPS (diluted)?
Amneal Pharmaceuticals, Inc. (AMRX) reported EPS (diluted) of $0.18 in Q2 2026.
How has Amneal Pharmaceuticals, Inc.'s EPS (diluted) changed year-over-year?
Amneal Pharmaceuticals, Inc.'s EPS (diluted) increased by 157.1% year-over-year, from $0.07 to $0.18.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s EPS (diluted)?
Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s EPS (diluted) has grown at a -35.6% compound annual growth rate (CAGR), from -$0.86 to $0.23.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Amneal Pharmaceuticals, Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude